CTKB
Cytek Biosciences, Inc.
CTKB has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CTKB overall, supported by stronger fundamentals and stronger modeled upside.
CTKB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
CTKB's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTKB PE Valuation
CTKB has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CTKB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CTKB's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CTKB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.54 |
| Q2 2026 | -$0.63 | -$0.58 |
| Q1 2026 | -$0.58 | -$0.49 |
| Q4 2025 | -$0.52 | -$0.47 |
| Q3 2025 | -$0.10 | -$0.02 |
| Q2 2025 | -$0.05 | +$0.09 |
| Q1 2025 | -$0.09 | $0.00 |
| Q4 2024 | -$0.05 | +$0.04 |
CTKB lost $0.64 per share over the past year, and its loss has widened in each of the last five quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CTKB on earnings quality, reporting a profit while its opponent remains loss making.
CTKB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $53.2M | +1.8% |
| Q2 2026 | $48.1M | +5.6% |
| Q1 2026 | $44.1M | +6.5% |
| Q4 2025 | $62.1M | +8.1% |
| Q3 2025 | $52.3M | +1.5% |
| Q2 2025 | $45.6M | -2.2% |
| Q1 2025 | $41.5M | -7.6% |
| Q4 2024 | $57.5M | -1.3% |
CTKB's revenue has grown year over year for five quarters in a row: $53M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +1.8 points |
| Q2 2026 | -24% | -0.4 points |
| Q1 2026 | -42% | -5.7 points |
| Q4 2025 | -9% | -14 points |
| Q3 2025 | -18% | -9.3 points |
| Q2 2025 | -23% | -5 points |
| Q1 2025 | -36% | -12 points |
| Q4 2024 | 5.2% | +5.4 points |
CTKB's operating margin was −16% last quarter, up 1.8 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CTKB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CTKB on profitability, with a higher operating margin.
CTKB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6M | -$1.4M |
| Q2 2026 | -$849K | +$620K |
| Q1 2026 | -$4.9M | -$3.9M |
| Q4 2025 | -$1.8M | -261% |
| Q3 2025 | -$4.6M | -137% |
| Q2 2025 | -$1.5M | -129% |
| Q1 2025 | -$974K | -129% |
| Q4 2024 | $1.1M | -86% |
CTKB has burned cash in seven of the last eight quarters: −$13M over the past year, against −$6M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CTKB on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTKB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +898K shares |
| 1 year | +2.2% | +2.8M shares |
| 3 years | -4.3% | -5.8M shares |
| 5 years | +260% | +94.2M shares |
| Available history | +6% | +7.3M shares |
CTKB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $34,000 |
| Q3 2025 | $29,000 |
| Q2 2025 | $4.5M |
| Q1 2025 | $10.6M |
| Q4 2024 | $7M |
CTKB has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CTKB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -431.1x | Net Cash |
| Q3 2022 | -185.1x | Net Cash |
| Q2 2022 | -100.0x | Net Cash |
| Q1 2022 | -48.1x | Net Cash |
| Q4 2021 | -37.2x | Net Cash |
| Q3 2021 | -23.1x | Net Cash |
| Q2 2021 | -7.9x | Net Cash |
| Q1 2021 | -10.0x | Net Cash |
CTKB has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CTKB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.6 | Neutral |
| Stochastic | 77.2 | Neutral |
CTKB's weekly RSI is 57 (neutral) and its Stochastic is 77 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CTKB PE vs Healthcare Sector
| Metric | CTKB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTKB has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CTKB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 2.5% below |
| 20 week MA | $5.04 | 9.5% above |
| 50 week MA | $4.73 | 17% above |
| 100 week MA | $4.50 | 23% above |
| 200 week MA | $5.95 | 7.2% below |
CTKB's trend is mixed: it's above three of its five weekly moving averages, and 7.2% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CTKB on trend strength, trading above more of its moving averages.
CTKB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.8 | $17.3 | -8% |
| 2022 | $17.3 | $10.1 | -41% |
| 2023 | $10.1 | $9.12 | -9.9% |
| 2024 | $9.12 | $6.39 | -30% |
| 2025 | $6.39 | $5.10 | -20% |
| 2026 YTD | $5.10 | $5.52 | +8.2% |
CTKB has finished every year since 2021 lower, and it's up 8.2% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CTKB on returns for 2026, with the stronger performance.